期刊
INTERNATIONAL JOURNAL OF OBESITY
卷 39, 期 1, 页码 156-161出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ijo.2014.101
关键词
-
资金
- Clinical Science Research and Development Service of the VA Office of Research and Development [1I01CX000422-01A1]
- Cooperative Studies Program/ERIC, US Department of Veterans Affairs and is a research component of the Massachusetts Veterans Epidemiology Research and Information Center
- Research Career Scientist award from the Clinical Science Research and development service, US department of veterans' affairs
- Spanish Ministry of Health [FIS 2011-00214]
- CIBERobn Fisiopatologia de la Obesidad y la Nutricion (CIBERobn)
INTRODUCTION: Irisin is a newly discovered myokine, associated with 'browning' of the white adipose tissue, obesity, insulin resistance and metabolic syndrome. The purpose of this study is to evaluate circulating irisin as a predictor of acute coronary syndromes (ACSs) and major adverse cardiovascular events (MACE). METHODS: Sub-study 1: a case-control study, nested within the Veteran's Affairs Normative Ageing Study, evaluating circulating irisin levels in 88 ACS cases and 158 age-and sampling year-matched controls, as a predictor of ACS. Sub-study 2: a prospective cohort study, where 103 participants with established coronary artery disease were stratified by circulating irisin levels at the time they received percutaneous coronary interventions (PCIs) and were followed for the development of MACE. RESULTS: Study 1: there was no association between irisin levels and ACS in otherwise healthy individuals (odds ratio: 1.00 95% confidence interval: (0.99-1.00)). Study 2: the incidence of MACE was significantly lower in the first irisin tertile compared with the second and third (incidence rate 0 vs 0.92 (0.51-1.61) vs 0.57 (0.28-1.14) events per 1000 person-days; P<0.01). This was primarily driven by the lower incidence of unstable angina (incidence rate 0 vs 0.61 (0.31-1.22) vs 0.43 (0.19-0.96) per 1000 person-days; P = 0.01). CONCLUSION: This is the first study to date that demonstrates that, although circulating irisin levels do not predict the development of ACS in healthy individuals, increased irisin levels are associated with the development of MACE in patients with established coronary artery disease after PCI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据